NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces that it has received approval from the Korean Intellectual Property Office for the issuance of its patent (application No. 10-2018-7032224) relating to NFL-101, a botanical drug candidate composed of natural proteins extracted from tobacco leaves, free of nicotine, and primarily intended for smoking cessation. This patent will protect the innovation on which NFL-101 is based until 2036 in South Korea.
NFL Biosciences has adopted a knowledge management and protection strategy that has led it to file two families of patents granting it exclusivity for its drug candidate NFL-101. This product patent, initially filed and approved in France, relates to an “aqueous extract of tobacco leaf and its use for the treatment of addiction”. The innovation on which NFL-101 is based is thus protected until 2036 in France, the United States, China and therefore now in South Korea. National registration applications are also being examined in the following regions and countries: Japan, Canada, Australia, Brazil, India, Indonesia, Israel, Mexico, Philippines, Eurasia, Saudi Arabia, United Arab Emirates, Nigeria.